CRP and COVID-19: Clinical research has demonstrated that hospitalized COVID-19 patients frequently exhibit CMBs accompanied by elevated levels of inflammatory markers including C-reactive protein, procalcitonin, tumour necrosis factor alpha and soluble interleukin-2 receptor.84 Additionally, there is a notable presence of consumptive coagulopathy in COVID-19 patients, characterized by increased levels of D-dimer and fibrinogen degradation products.